Status:

NOT_YET_RECRUITING

Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry

Lead Sponsor:

Sensimed AG

Conditions:

Glaucoma

Ocular Hypertension

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of glaucoma. IOP is known to ...

Eligibility Criteria

Inclusion

  • Informed Consent
  • A clinical diagnosis of primary open angle glaucoma (POAG), including normal tension glaucoma (NTG), for OAG patients
  • A clinical diagnosis of OHT, for OHT patients
  • For all patients:
  • Open angles on gonioscopy Aged ≥ 18 years, either gender Both central corneal radii (CCR) between 7.3mm (46.23D) and 8.05mm (41.93D), with a maximum difference of 2D between the 2 radii in the study eye Central corneal thickness (CCT) between 490µm and 600µm in the study eye

Exclusion

  • Ocular pathology (other than glaucoma or OHT)
  • Previous glaucoma, cataract or refractive laser/surgery
  • Corneal or conjunctival abnormality, precluding contact lens adaptation
  • Insufficiency of lacrimal secretion
  • Subjects with allergy to corneal anesthetic
  • Subjects with contraindications for silicone contact lens wear
  • Subjects with contraindications for Diamox or Latanoprost or Timolol
  • Skin irritations, skin eczema or other indications against the wearing of adhesive patches
  • Subjects unable or unwilling to comply with the study procedures
  • Subjects lacking the capacity to consent (vulnerable persons)
  • Subjects with history of cardiac failure, treated cardiopathy or renal failure
  • Subjects with known cognitive disorders
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

Key Trial Info

Start Date :

July 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT04024293

Start Date

July 1 2025

End Date

December 1 2025

Last Update

May 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinique Montchoisi

Lausanne, Canton of Vaud, Switzerland, 1006